Cleerly LABS vs AI-ECG Platform
AI Verdict
Choose Cleerly LABS if…
Choose Cleerly LABS if your primary need is a comprehensive, AI-powered anatomical assessment of coronary arteries to detect, quantify, and characterize atherosclerosis and stenosis. This tool is ideal for personalized heart disease management, allowing for detailed plaque analysis and tracking disease progression over time in patients requiring in-depth CCTA interpretation.
View Cleerly LABS →Choose AI-ECG Platform if…
Choose the AI-ECG Platform if you require rapid, highly accurate AI-assisted interpretation of 12-lead resting ECGs for initial diagnosis and screening of major cardiovascular diseases. This platform is particularly well-suited for high-volume clinical settings, such as emergency medicine or general cardiology, where quick identification of arrhythmias, myocardial ischemia, or hypertrophy is critical for timely patient management.
View AI-ECG Platform →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly LABS | AI-ECG Platform |
|---|---|---|
| Pricing | Varies | Unknown |
| Deployment | Cloud, On-premise | On-premise (AI-ECG Workstation), web-based (Management Portal), and client-based (AI-ECG Diagnostic Client). |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Cleerly LABSCleerly LABS offers a modern, purely web-based application with advanced 3D visualization and seamless integration capabilities via its Cleerly Proxy, enhancing the user experience. While the AI-ECG Platform provides a web-based portal and rapid diagnosis, its reliance on a Windows-based diagnostic client and workstation deployment may introduce more complexity compared to Cleerly's cloud-native approach.
Clinical Value
Cleerly LABSCleerly LABS provides a more profound and proactive clinical value through comprehensive, quantitative analysis of coronary plaque and stenosis from CCTA, enabling personalized risk assessment and tracking disease progression over time. Its ischemia detection module has been clinically validated against invasive FFR, demonstrating high diagnostic accuracy. The AI-ECG Platform offers high accuracy for ECG interpretation, but Cleerly's detailed plaque characterization and prognostic insights represent a more advanced and potentially transformative impact on patient management and preventative care.
Pricing & Value
Cleerly LABSCleerly LABS offers transparent pricing with a clear per-analysis cost and has made significant progress in securing insurance coverage from major payers like UnitedHealthcare, Cigna, and Aetna, enhancing its accessibility and value. In contrast, the AI-ECG Platform's lack of public pricing information makes it challenging for potential users to assess its cost-effectiveness or overall value proposition.
Enterprise Readiness
Cleerly LABSCleerly LABS demonstrates stronger enterprise readiness with explicit statements of BAA and HIPAA compliance, a fully cloud-based (AWS) architecture, and a dedicated Cleerly Proxy for seamless integration with PACS, RIS, and EHR systems. The AI-ECG Platform's 'likely' compliance status and mixed deployment options, including a Windows client, suggest a slightly less robust and standardized enterprise offering compared to Cleerly's clear compliance and cloud-native approach.
Innovation
Cleerly LABSCleerly LABS exhibits greater innovation by leveraging AI for comprehensive and quantitative analysis of CCTA images, focusing on detailed plaque characterization, stenosis, and ischemia detection to establish a new standard of care for heart disease prevention. While the AI-ECG Platform provides valuable high-accuracy and rapid ECG interpretation, AI applications in CCTA for detailed plaque phenotyping and progression tracking are more groundbreaking and potentially paradigm-shifting in cardiology.
Support & Docs
Cleerly LABSCleerly LABS explicitly outlines its client support availability, including specific hours of operation (Monday-Friday, 10 am ET to 6 pm ET) and a dedicated contact method for existing users, along with mentioning implementation specialists for setup. The AI-ECG Platform lacks specific public information regarding its support structure, documentation, or implementation services, making it difficult to assess its robustness in this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly LABS | AI-ECG Platform |
|---|---|---|
| Name | Cleerly LABS | AI-ECG Platform |
| Company | Cleerly | Shenzhen Carewell Electronics Co., Ltd. |
| Description | AI-powered, FDA-cleared web-based software for comprehensive analysis of coronary CT angiography (CCTA) to detect, quantify, and characterize atherosclerosis and stenosis, aiding in personalized heart disease management. | FDA-cleared artificial intelligence (AI) automatic analysis and diagnosis system for ECG, designed to assist physicians in interpreting 12-lead resting ECGs with high accuracy. |
| Primary Modality | Coronary CT Angiography (CCTA) | 12-lead resting ECG |
| Key Feature 1 | AI-powered CCTA image analysis | AI-powered automatic ECG analysis and diagnosis |
| Key Feature 2 | Comprehensive coronary plaque assessment (volume, type) | Over 95% accuracy in diagnosing major cardiovascular diseases |
| Key Feature 3 | Stenosis detection and quantification | Diagnoses arrhythmias, ventricular hypertrophy, myocardial ischemia, and myocardial infarction |
Videos
Demos, reviews, and walkthroughs featuring Cleerly LABS and AI-ECG Platform.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly LABS or AI-ECG Platform
Backers
Who funded each tool's parent company.